Abedinejad Majid, Hadian Mohammad, Behrooj Soudabe, Bagheri Faradonbeh Saeed, Saniee Nadia
Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Hormozgan Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Med J Islam Repub Iran. 2024 Sep 9;38:103. doi: 10.47176/mjiri.38.103. eCollection 2024.
One of the most important causes of mortality in the world is acute myocardial infarction. There are two general treatments including thrombolytic drugs and percutaneous coronary interventions. But, monitoring outpatient AMI treatment from a remote or rural location has emerged as a successful telemedicine technique. So, the present study aimed to review the economic evaluation studies of telemedicine in patients with acute myocardial infarction.
This study was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis checklist (PRISMA is a 27-item checklist used to improve transparency in systematic reviews) guidelines in 2022. PubMed, Scopus, Web of Science, Proquest, Iranian databases (SID, Magiran), and Google Scholar were searched with the keywords of telemedicine and myocardial infarction from 2000 to 2022. After eliminating duplicates, titles and abstracts were screened based on inclusion and exclusion criteria, details, and the most important results of eligible studies were recorded in the data collection form.
904 records were identified in this search, of which 147 were duplicates. Finally, 6 records were included in this study. Among these studies, 4 were cost-effectiveness, one was cost analysis, and one was cost-utility. The willingness to pay threshold was between 20,000 and 100,000, and the outcomes were measured with QALY (Quality-adjusted life-years). The reviewed studies showed that telemedicine can improve outcomes such as quality of life and reduce disease costs.
The results showed that telemedicine interventions for acute myocardial infarction can be helpful, and cost-effective. However in some cases, it can cause increased costs and may not have a significant difference in effectiveness with other methods because of the condition and stage of the disease.
全球死亡的最重要原因之一是急性心肌梗死。有两种常规治疗方法，包括溶栓药物和经皮冠状动脉介入治疗。但是，从偏远或农村地区对门诊急性心肌梗死患者进行治疗监测已成为一种成功的远程医疗技术。因此，本研究旨在综述急性心肌梗死患者远程医疗的经济学评价研究。
本研究于2022年根据系统评价和Meta分析的首选报告项目清单（PRISMA是一个包含27个条目的清单，用于提高系统评价的透明度）指南进行。在PubMed、Scopus、科学网、ProQuest、伊朗数据库（SID、Magiran）和谷歌学术中，使用“远程医疗”和“心肌梗死”作为关键词，检索2000年至2022年的文献。在排除重复文献后，根据纳入和排除标准筛选标题和摘要，将符合条件研究的详细信息和最重要结果记录在数据收集表中。
本次检索共识别出904条记录，其中147条为重复记录。最终，本研究纳入了6条记录。在这些研究中，4条为成本效益分析，1条为成本分析，1条为成本效用分析。支付意愿阈值在20000至100000之间，结局指标采用质量调整生命年（QALY）进行衡量。综述研究表明，远程医疗可以改善生活质量等结局，并降低疾病成本。
结果表明，针对急性心肌梗死的远程医疗干预可能是有益且具有成本效益的。然而，在某些情况下，由于疾病的状况和阶段，它可能会导致成本增加，并且与其他方法相比在有效性上可能没有显著差异。
